Its these real-world outcomesnot just clinical studiesthat highlight the impact of making semaglutide treatment accessible, especially for those previously left out of the conversation
12:546-556 Park J, Ntelis S, Yunasan E, Downton KD, Yip TC, Munir KM, et al
Many patients benefit from combining both for optimal rejuvenation
The largest clinical trials of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in type 1 diabetes have been conducted with liraglutide 1.8 mg daily, and results showed modest A1C reductions (0.4%), decreases in weight (5 kg), and reductions in insulin doses (65,66)
Communicate with your Noom Med clinician: Regular communication helps your clinician monitor your progress and adjust treatment as needed
Ongoing surveillance is only recommended if extensive gastric atrophy, intestinal metaplasia, or additional risk factors are identified